机译:血清糖类抗原-125(CA-125)高水平预示着滤泡性淋巴瘤患者的预后不良,与FLIPI评分无关
Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc, I. P. Pavlova 6, 77520, Olomouc, Czech Republic;
Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc, I. P. Pavlova 6, 77520, Olomouc, Czech Republic;
Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc, I. P. Pavlova 6, 77520, Olomouc, Czech Republic;
Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc, I. P. Pavlova 6, 77520, Olomouc, Czech Republic;
Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic;
Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc, I. P. Pavlova 6, 77520, Olomouc, Czech Republic;
Department of Hemato-Oncology, Faculty of;
Follicular lymphoma; Chemotherapy; Autologous transplantation; CA-125; Prognosis;
机译:血清糖抗原125(CA-125)高水平预示着滤泡性淋巴瘤患者的不良预后与FLIPI评分无关
机译:IL-2R,IL-6和TNF-α的高血清水平与RITuximab时代的卵泡淋巴瘤患者的肿瘤负担和较差的结果有关
机译:滤泡性淋巴瘤患者的APRIL高而不是BAFF血清水平与预后不良有关
机译:鉴定卵腔淋巴瘤患者总生存的基因重要性
机译:使用临床途径评分预测颅脑外伤患者的临床结果
机译:术前血清CA 19-9水平高可通过倾向评分分析预测大肠癌患者的不良肿瘤预后
机译:高术前血清CA 19-9水平可以预测结肠直肠癌患者肝癌患者的贫瘠结果